Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G)

BACKGROUND: Trifluridine/tipiracil (FTD/TPI) prolongs survival in the third- or later-line treatment for advanced gastric cancer (GC), esophagogastric junction (EGJ) adenocarcinoma, and colorectal cancer. While single-arm phase II trials showed promising outcomes of FTD/TPI plus ramucirumab (RAM) as...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Naoki, Hara, Hiroki, Nagashima, Kengo, Hirata, Kenro, Masuishi, Toshiki, Matsumoto, Toshihiko, Kawakami, Hisato, Yamazaki, Kentaro, Hironaka, Shuichi, Boku, Narikazu, Muro, Kei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403909/
https://www.ncbi.nlm.nih.gov/pubmed/37543568
http://dx.doi.org/10.1186/s12885-023-11199-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403909/
https://www.ncbi.nlm.nih.gov/pubmed/37543568
http://dx.doi.org/10.1186/s12885-023-11199-1

Ejemplares similares